In a randomized, double-blind, placebo-controlled trial of tenofovir disoproxil fumarate (TDF) use from 28 weeks gestational age to 2 months postpartum to prevent mother-to-child transmission of hepatitis B virus, there was no significant effect of maternal TDF use on maternal or infant bone mineral density 1 year after delivery/birth. Clinical Trials Registration. NCT01745822 .
All Keywords
【저자키워드】 Pregnancy, tenofovir disoproxil fumarate, hepatitis B, bone mineral density, growth,
【저자키워드】 Pregnancy, tenofovir disoproxil fumarate, hepatitis B, bone mineral density, growth,